

7. Andersen T. Arteritis temporalis (Horton): a survey and a case with glaucoma. *Acta Med Scand.* 1947; 128: 151–178.
8. McMillan GC. Diffuse granulomatous aortitis with giant cells associated with partial rupture and dissection of the aorta. *AMA Arch Pathol.* 1950; 49(1): 63–69.
9. Olhagen B. Polymyalgia rheumatica: a form of senile arteritis? *Acta Rheumatol Scand.* 1963; 9: 157–164.
10. Hamrin B, Jonsson N, Landberg T. Arteritis in "polymyalgia rheumatica." *Lancet* 1964; 1: 397–401.
11. Alestig K, Barr J. Giant-cell arteritis. A biopsy study of polymyalgia rheumatica, including one case of Takayasu's disease. *Lancet.* 1963; 1(7293): 1228–1230.
12. Cantini F, Niccoli L, Storri L et al. Are Polymyalgia Rheumatica and Giant Cell Arteritis the Same Disease? *Semin Arthritis Rheum* 2004; 33(5): 294–301.
13. Kermani TA. Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease? *Int J Rheum Dis* 2019; 22: 41–48.
14. Sharma A, Mohammad AJ, Turesson C. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. *Semin Arthritis Rheum.* 2020; 50(5): 1040–1048.
15. Crowson CS, Matteson EL. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. *Semin Arthritis Rheum.* 2017; 47(2): 253–256.
16. Mackie SL, Taylor JC, Haroon-Rashid L et al. Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. *Arthritis Res Ther.* 2015; 17(1): 195.
17. Verdijk RM, Ouwendijk WJD, Kuipers RWAM, Verjans GMGM. No Evidence of Varicella-Zoster Virus Infection in Temporal Artery Biopsies of Anterior Ischemic Optic Neuropathy Patients With and Without Giant Cell Arteritis. *J Infect Dis.* 2021; 4: 223(1): 109–112.
18. Watanabe R, Goronzy JJ, Berry G, Liao YJ, Weyand CM. Giant Cell Arteritis: From Pathogenesis to Therapeutic Management. *Curr Treatm Opt Rheumatol.* 2016; 2(2): 126–137.
19. Imai N, Kuroda R, Konishi T, Serizawa M, Kobari M. Giant cell arteritis: clinical features of patients visiting a headache clinic in Japan. *Intern Med* 2011; 50(16): 1679–1682.
20. Mollan SP, Paemeleire K, Versijpt J et al. European Headache Federation recommendations for neurologists managing giant cell arteritis. *J Headache Pain* 2020; 21, 28.
21. Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids: Results in 55 cases in which the lesion was proved at biopsy. *J Am Med Assoc.* 1957; 163(10): 821–827.
22. Singh AG, Kermani TA, Crowson CS et al. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. *J Rheumatol* 2015; 42: 309–315.
23. Patil P, Williams M, Maw WW et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. *Clin Exp Rheumatol.* 2015; 33 (2 Suppl 89): S-103-6.
24. Vodopivec J, Rizzo, III JF. Ophthalmic manifestations of giant cell arteritis, *Rheumatology* 2018; 57: ii63–ii72.
25. Chen JJ, Leavitt JA, Fang C et al. Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. *Ophthalmology* 2016; 123(9): 1999–2003.
26. Peral-Cagigal B, Pérez-Villar Á, Redondo-González LM et al. Temporal headache and jaw claudication may be the key for the diagnosis of giant cell arteritis. *Med Oral Patol Oral Cir Bucal.* 2018; 23(3): e290–e294.
27. Larivière, Delphine et al. Extra- and intracranial cerebral vasculitis in giant cell arteritis: an observational study. *Medicine* 2014; 93(28): e265.
28. Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. *Semin Arthritis Rheum.* 1995; 24(6): 422–431.
29. Nueninghoff DM, Hunder GG, Christianson TJ et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. *Arthritis Rheum* 2003; 48: 3532–3537.
30. Greigert H, Zeller M, Putot A et al. Myocardial infarction during giant cell arteritis: A cohort study. *Eur. J. Intern Med* 2021; 17: S0953-6205(21)00038-8.
31. Zenone T. Fever of unknown origin in rheumatic diseases. *Infect Dis Clin North Am.* 2007; 21(4): 1115–1135, x–xi.
32. Milchert M, Brzosko M. Tunnel Vision in a Patient with Polymyalgia Rheumatica. *J Rheumatol.* 2020; 47(1): 155–156.
33. Prior JA, Ranjbar H, Belcher J et al. Diagnostic delay for giant cell arteritis – a systematic review and meta-analysis. *BMC Med* 2017; 15: 120.
34. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. *Arthritis Rheum.* 1990; 33: 1122–1128.
35. Murchison AP, Gilbert ME, Bilyk JR et al. Validity of the American College of Rheumatology criteria for the diagnosis of giant cell arteritis. *Am J Ophthalmol.* 2012; 154(4): 722–729.
36. van der Geest KSM, Weyel H, Abdulahad WV et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica, *Rheumatology* 2015; 54(8): 1397–1402.
37. Hellmich B, Agueda A, Monti S et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis* 2020; 79 (1): 19–30.
38. Mackie SL, Dejaco C, Appenzeller S et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis, *Rheumatology* 2020; 59(3): e1–e23.
39. Chu R, Foster C, Ali M et al. Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records. *Lancet Rheumatol* 2020; 2(12): E 744–E 778.
40. Dasgupta B. Giant Cell Arteritis Guideline Development Group. Concise guidance: diagnosis and management of giant cell arteritis. *Clin Med (Lond).* 2010; 10(4): 381–386.
41. Stacy RC, Rizzo JF, Dean M, Cestari DM. Subtleties in the Histopathology of Giant Cell Arteritis. *Seminars in Ophthalmology* 2011; 26: 4–5, 342–348.
42. Dejaco C, Ramiro S, Duftner C et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice *Ann Rheum Dis* 2018; 77(5): 636–643.
43. Luqmani R, Lee E, Singh S et al. The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. *Health Technol Assess.* 2016; 20(90): 1–238.
44. Theunissen P, Kliffen M, Dees A. Giant-cell Arteritis of the Ovarian Arteries: A Rare Manifestation of a Common Disease. *Eur J Case Rep Intern Med.* 2018; 5(5): 000779.
45. Blockmans, D. Use of FDG-PET Scan for the Assessment of Large Vessel Vasculitis. *Curr Treat Options in Rheum* 2016; 2: 153–160.
46. Ray-Chaudhuri N, Kiné DA, Tijani SO et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. *Br J Ophthalmol.* 2002; 86(5): 530–532.
47. Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? *Ann Intern Med.* 1994; 120(12): 987–992.
48. Narváez B, Bernad D, Roig-Vilaseca C et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. *Semin Arthritis Rheum* 2007; 37: 13–19.
49. Hellmich B, Águeda AF, Monti S et al. Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future. *Curr Rheumatol Rep* 2020; 22, 84.
50. Strehl C, Bijlsma JWJ, de Wit M et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. *Ann Rheum Dis.* 2016; 75(6): 952–957.
51. Ponte C, Rodrigues AF, O'Neill L, Luqmani RA. Giant cell arteritis: Current treatment and management. *World J Clin Cases* 2015; 3(6): 484–494.
52. Koster MJ, Yeruva K, Crowson CS, Muratore F, Labarca C, Warrington KJ. Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study. *J Rheumatol.* 2019; 46(5): 501–508.
53. Mahr AD, Jover JA, Spiera RF et al. Adjunctive Methotrexate for Treatment of Giant Cell Arteritis. An Individual Patient Data Meta-Analysis. *Arth Rheum* 2007; 56(8): 2789–2797.
54. Stone JH, Tuckwell K, Dimonaco S et al. Trial of Tocilizumab in Giant-Cell Arteritis. *N Engl J Med.* 2017; 27; 377(4): 317–328.
55. Harrington R, Al Nokhatha SA, Conway R. Biologic Therapies for Giant Cell Arteritis. *Biologics.* 2021; 15: 17–29.
56. Sugihara T, Hasegawa H, Uchida HA et al. Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. *Arthritis Res Ther* 2020; 22(72): 1–12.
57. Maleszewski JJ, Younge BR, Fritzlen JT et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. *Mod Pathol.* 2017; 30(6): 788–796.
58. Neshor G, Poltorak V, Hindi I et al. Survival of patient with giant cell arteritis: Impact of vision loss and treatment with aspirin. *Autoimmun Rev.* 2019; 18(8): 831–834.
59. Dinkin M, Johnson E. One Giant Step for Giant Cell Arteritis: Updates in Diagnosis and Treatment. *Curr Treat Options Neurol* 2021; 23: 6.
60. Turesson C, Börjesson O, Larsson K, Mohammad AJ, Knight A. Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis. *Scand J Rheumatol.* 2019; 48(4): 259–265.
61. Crow RW, Katz BJ, Warner JE et al. Giant cell arteritis and mortality. *J Gerontol A Biol Sci Med Sci.* 2009; 64(3): 365–369.
62. Hill CL, Black RJ, Nossent JC, Ruediger C, Nguyen L, Ninan JV et al. Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. *Semin Arthritis Rheum* 2017; 46: 513–519.
63. Mohammad AJ, Nilsson JA, Jacobsson LT, Merkel PA, Turesson C. Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. *Ann Rheum Dis* 2015; 74: 993–997.